Bruno Flamion

Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium

Frank Dieterle, Frank D. Sistare, Federico Goodsaid et al. · Nature Biotechnology · 2010 · 406 citations

Medicine, Nephrology, Precision Medicine +13

Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma

Ilse Vlassenbroeck, Stèphane Califice, Annie‐Claire Diserens et al. · Journal of Molecular Diagnostics · 2008 · 200 citations · Full text

Medicine, Genetics, Molecular Biology +14

Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency

Jan Regnström, Franz Koenig, B. Aronsson et al. · European Journal of Clinical Pharmacology · 2009 · 128 citations · Full text

Pharmacy, Pharmaceutical Policy, Regulatory Pharmacy +12

Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium Guidance

Anjan K. Banerjee, Sally Okun, I. Ralph Edwards et al. · Drug Safety · 2013 · 121 citations · Full text

Pharmacy, Health Services Administration, Clinical Epidemiology +15

Skeletal and hematological anomalies in HYAL2‐deficient mice: a second type of mucopolysaccharidosis IX?

Laurence Jadin, Xiaoli Wu, Hao Ding et al. · The FASEB Journal · 2008 · 94 citations · Full text

Medicine, Molecular Genetics, Pathobiology +14